Protective effectiveness of previous SARS-CoV-2 infection and hybrid immunity against the omicron variant and severe disease: a systematic review and meta-regression-Reference-Cited by-同舟云学术

Protective effectiveness of previous SARS-CoV-2 infection and hybrid immunity against the omicron variant and severe disease: a systematic review and meta-regression

Published:2023-05 Issue:5 Volume:23 Page:556-567
ISSN:1473-3099
Container-title:The Lancet Infectious Diseases
language:en
Short-container-title:The Lancet Infectious Diseases

Author:

Bobrovitz Niklas,Ware Harriet,Ma Xiaomeng,Li Zihan,Hosseini Reza,Cao Christian,Selemon Anabel,Whelan Mairead,Premji Zahra,Issa Hanane,Cheng Brianna,Abu Raddad Laith J,Buckeridge David L,Van Kerkhove Maria D,Piechotta Vanessa,Higdon Melissa M,Wilder-Smith Annelies,Bergeri Isabel,Feikin Daniel R,Arora Rahul K,Patel Minal K,Subissi Lorenzo

Funder

World Health Organization

Coalition for Epidemic Preparedness Innovations

Publisher

Elsevier BV

Subject

Infectious Diseases

Reference36 articles.

1. Reinfection with new variants of SARS-CoV-2 after natural infection: a prospective observational cohort in 13 care homes in England;Jeffery-Smith;Lancet Healthy Longev,2021

2. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine;Polack;N Engl J Med,2020

3. Global SARS-CoV-2 seroprevalence from January 2020 to April 2022: a systematic review and meta-analysis of standardized population-based studies;Bergeri;PLoS Med,2022

4. COVID-19 vaccine hesitancy worldwide: a concise systematic review of vaccine acceptance rates;Sallam;Vaccines,2021

5. Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression;Feikin;Lancet,2022

Cited by 216 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Understanding SARS-CoV-2 spike glycoprotein clusters and their impact on immunity of the population from Rio Grande do Norte, Brazil;Infection, Genetics and Evolution;2024-03

2. Counterfactual analysis of the 2023 Omicron XBB wave in China;Infectious Disease Modelling;2024-03

3. Hybrid immunity to SARS‐CoV‐2 in patients with chronic lymphocytic leukemia;European Journal of Haematology;2024-02-04

4. Early Estimates of Updated 2023–2024 (Monovalent XBB.1.5) COVID-19 Vaccine Effectiveness Against Symptomatic SARS-CoV-2 Infection Attributable to Co-Circulating Omicron Variants Among Immunocompetent Adults — Increasing Community Access to Testing Program, United States, September 2023–January 2024;MMWR. Morbidity and Mortality Weekly Report;2024-02-01

5. Anti-SARS-CoV-2 IgG antibody after the second and third mRNA vaccinations in staff and residents in a nursing home with a previous COVID-19 outbreak in Niigata, Japan;Journal of Infection and Chemotherapy;2024-02